| Autor: |
Pang, Alan L. Y., Hashimoto, Caryn N., Tam, Leslie Q., Meng, Z. Q., Hui, George S. N., Ho, Walter K. K. |
| Zdroj: |
Infection and Immunity; June 2002, Vol. 70 Issue: 6 p2772-2779, 8p |
| Abstrakt: |
ABSTRACTThe 42-kDa carboxyl-terminal processing fragment of Plasmodium falciparummerozoite surface protein 1 (MSP-142) is an anti-erythrocytic stage malaria vaccine candidate. In this study, MSP-142was expressed by using the Bombyx morinuclear polyhedrosis virus-silkworm expression system, and the antigenicity and immmunogenicity of the recombinant protein, Bmp42, were evaluated. The average yield of Bmp42, as determined by a sandwich enzyme-linked immunosorbent assay (ELISA), was 379 μg/ml of infected silkworm hemolymph, which was >100-fold higher than the level attainable in cell culture medium. N-terminal amino acid sequencing revealed that Bmp42 was correctly processed in silkworm cells. Data from immunoblotting, as well as from the inhibition ELISA, suggested that the conformational B-cell epitopes of MSP-142were recreated in Bmp42. Immunization of rabbits with Bmp42 in complete Freund's adjuvant generated high-titer antibody responses against the immunogen. Specificity analyses of the anti-Bmp42 antibodies using several recombinant MSP-119proteins expressing variant and conserved B-cell epitopes suggested that the anti-Bmp42 antibodies recognized primarily conserved epitopes on MSP-119. Furthermore, the anti-Bmp42 antibodies were highly effective in inhibiting the in vitro growth of parasites carrying homologous or heterologous MSP-142. Our results demonstrated that the baculovirus-silkworm expression system could be employed to express biologically and immunologically active recombinant MSP-142at elevated levels; thus, it is an attractive alternative for producing a protective MSP-142vaccine for human use. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
